Monday, April 20, 2026

9:40 AM - 11:10 AM

Room 4, Upper Level

---

Details

Over the last decade, the understanding of molecular and other drivers of acute myeloid leukemia (AML) has led to the development of novel agents, disease reclassification and revaluation of risk scores in newly diagnosed and relapsed/refractory AML.  This session focuses on this changing landscape in the management of AML. The routine use of next-generation sequencing methods has underscored the genetic and clonal heterogeneity of AML, ushering in an era of precision medicine in AML. This advent of targeted drugs in AML, exemplified by the small-molecule inhibitors of FLT3, IDH1/IDH2, BCL2 and menin, has broadened the spectrum of antileukemic therapies available and expanded the possibilities for the fit and unfit patients. Alongside, there has been a refinement of risk stratifications and developments in the measurement of residual disease (MRD) allowing further tailoring of treatment for patients. Selecting frontline treatment for patients, intensive and non intensive, requires considerations of fitness/ frailty and disease biology to optimise outcomes. Improved induction therapy, better patient selection and advances in the delivery of allogeneic stem cell transplant(SCT) could potentially make SCT amenable for a larger number of AML patients where it remains the best chance of cure. In this session we aim to discuss the ‘current best practice’ and future possibilities in managing the dilemmas that arise in the course of treating newly diagnosed and relapsed/ refractory AML patients.

---

Speaker